表 2.
健康对照组与RA患者组的基线临床特征比较
Comparisons of baseline characteristics between RA patients and healthy controls
| Items | HC(n=51) | Non-myopenia RA patients (n=51) | Myopenia RA patients (n=51) | All RA patients(n=102) | Statistics | P |
| HC, healthy controls; RA, rheumatoid arthritis; ASMI, appendicular skeletal muscle mass index; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated protein antibodies; 28TJC, 28 tender joint counts; 28SJC, 28 swollen joint counts; PtGA, patient global assessment of disease activity; PrGA, physician global assessment of disease activity; VAS, visual analogue scale; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CDAI, clinical disease activity index; HAQ-DI, health assessment questionnaire-disability index; mTSS, modified total Sharp score. a, comparison among HC, non-myopenia RA patients and myopenia RA patients; b, comparison of HC to all RA patients; c, comparison of non-myopenia RA patients to myopenia RA patients. * showing 2-sided significancy of Fisher’ s exact test between HC and all RA patients. | ||||||
| Female, n (%) | 44 (86.3) | 39(76.5) | 42(82.4) | 81 (79.4) | χ2 =2.753a | 0.252 |
| Age/years, x±s | 46.9±8.8 | 48.7±9.8 | 49.5±13.0 | 49.1±11.5 | F=0.811a | 0.446 |
| ASMI/(kg/m2), x±s | 6.31±0.73 | 6.81±0.67 | 5.23±0.63 | 6.0±1.0 | F=72.335a | < 0.001 |
| Myopenia, n (%) | 10 (19.6) | 0(0.0) | 51(100.0) | 51 (50.0) | - | < 0.001b* |
| Disease duration/month, M(Q1, Q3) | - | 39 (6, 111) | 65 (14, 133) | 41 (10, 120) | Z=-2.202c | 0.028 |
| Active smoking, n (%) | - | 7(13.7) | 6(11.8) | 13 (14.6) | χ2=0.088c | 0.767 |
| Positive RF, n (%) | - | 38(74.5) | 42(82.4) | 80 (78.4) | χ2=0.927c | 0.336 |
| Positive ACPA, n (%) | - | 37(72.5) | 41(80.4) | 78 (76.5) | χ2=0.872c | 0.350 |
| 28TJC, M (Q1, Q3) | - | 3 (1, 8) | 4 (1, 7) | 3 (1, 7) | Z=-0.199c | 0.842 |
| 28SJC, M (Q1, Q3) | - | 2 (1, 6) | 2 (0, 5) | 2 (1, 5) | Z=-0.149c | 0.882 |
| PtGA/cm, M (Q1, Q3) | - | 4 (2, 7) | 4 (3, 6) | 4 (2, 6) | Z=-0.236c | 0.814 |
| PrGA/cm, M (Q1, Q3) | - | 3 (2, 7) | 4 (3, 6) | 4 (2, 6) | Z=-0.508c | 0.611 |
| Pain VAS/cm, M (Q1, Q3) | - | 3 (2, 7) | 4 (2, 5) | 4 (2, 5) | Z=-0.784c | 0.433 |
| ESR/(mm/h), M (Q1, Q3) | - | 32 (19, 50) | 49 (24, 77) | 37 (21, 64) | Z=-2.534c | 0.011 |
| CRP/(mg/L), M (Q1, Q3) | - | 5.9 (3.3, 10.6) | 10.2 (3.3, 25.5) | 6.8 (3.3, 17.9) | Z=-1.581c | 0.114 |
| CDAI, M (Q1, Q3) | - | 13 (6, 28) | 16 (9, 23) | 14 (8, 24) | Z=-0.378c | 0.705 |
| Active disease, n (%) | 44 (86.3) | 43(84.3) | 87 (85.3) | χ2=0.078c | 0.780 | |
| HAQ-DI, M (Q1, Q3) | - | 0.25 (0.00, 1.00) | 0.50 (0.13, 1.25) | 0.38 (0.00, 1.06) | Z=-0.892c | 0.372 |
| Physical dysfunction, n (%) | 14 (27.5) | 15(29.4) | 29(28.4) | χ2=0.048c | 0.826 | |
| mTSS, M (Q1, Q3) | - | 5 (0, 32) | 11 (3, 46) | 8 (0, 36) | Z=-1.564c | 0.118 |
| Radiological joint destruction, n (%) | 19 (37.3) | 27 (52.9) | 46 (45.1) | χ2=2.534c | 0.111 | |